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Combined therapy with clopidogrel and aspirin
significantly increases the bleeding time through a
synergistic antiplatelet action
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A. R. Naylor, MD,a and A. H. Goodall, PhD,b Leicester, United Kingdom
Objective: Many thromboembolic events occur in patients taking aspirin. Dual therapy with aspirin and clopidogrel may
prove effective at reduction of thromboembolic complications. However, the extent to which these two drugs interact
may significantly increase the risk of bleeding in open surgery. Because of the increased use of combination antiplatelet
therapy in populations with significant atherosclerotic disease, this risk needs to be evaluated by the assessment of the
combined effect in vivo of clopidogrel and aspirin on bleeding time and platelet function.
Outcomes: In seven healthy subjects, addition of low dose clopidogrel (2  75 mg) to aspirin (150 mg) therapy
significantly increased bleeding time (from 7.6 3.4 minutes to 17.5 8.6 minutes; P < .05), with concomitant falls in
adenosine diphosphate (ADP)–induced platelet fibrinogen binding and aggregation (P < .05). Increasing the dose of
clopidogrel to 300 mg increased bleeding time (to 24.9  8.5 minutes; P < .05) without significant additional platelet
inhibition. There was considerable variability in the individual subject platelet response to the lower dose of clopidogrel.
Those patients with the highest ADP response at baseline had the least response, and subjects with a weak response to
ADP at baseline achieved maximal platelet inhibition with the low dose of clopidogrel.
Conclusion: The increases in bleeding times should be considered in combination antiplatelet therapy in patients who
undergo open vascular surgery. (J Vasc Surg 2002;35:1204-9.)
Despite advances in the management of symptomatic
atherosclerotic disease, thromboembolic complications still
occur at sites of plaque instability. Endothelial disruption
and platelet recruitment, activation, and aggregation are
fundamental to the pathogenesis of arterial thrombosis.1
Aspirin has been the mainstay of antiplatelet therapy, pre-
venting platelet aggregation with irreversibly inhibiting the
formation of thromboxane A2, which reinforces the effects
of other physiologic platelet agonists, such as adenosine
diphosphate (ADP) and collagen.2 Although a standard dose
of aspirin has been shown to reduce the risk of vascular
occlusion by as much as 25%,3 most arterial thrombotic events
still occur in patients who are currently taking aspirin.
Recent interest has focused on the novel group of anti-
platelet drugs, the theinopyridine derivatives, which act as
specific ADP receptor antagonists. Two drugs have been
licensed: ticlopidine hydrochloride and the related com-
pound, clopidogrel bisulfate, which gives rise to fewer adverse
side effects.4 The CAPRIE trial5 showed that long-term
therapy (mean, 1.91 years) with 75 mg per day clopidogrel
gave an overall reduction in thrombotic events compared
with 325 mg per day aspirin in patients at high risk of
vascular occlusion. This was particularly significant in patients
with peripheral arterial disease (relative risk reduction, 23.9%;
95% confidence interval, 8.9 to 36.2; P  .0028). The same
study also indicated that clopidogrel had a safer drug profile
than that of aspirin, with fewer hemorrhagic incidences.5-7
However, theinopyridines still gave only a modest improve-
ment over aspirin. The important issue is whether theinopyri-
dines add to the benefit seen with aspirin without increasing
the risk of bleeding. It is likely that increasing numbers of
patients attending for vascular surgical procedures will be
undergoing combination antiplatelet therapy. This may be of
particular relevance in the acute setting, including intravascu-
lar interventions.
Studies in patients undergoing carotid endarterectomy
have shown that, despite the use of aspirin and heparin
therapy, thromboembolic events still occur after surgery8
and increasing rates of postoperative embolization are as-
sociated with a significantly higher risk of thromboembolic
stroke.9,10 The ASA and Carotid Endarterectomy Trial
showed that there may be a beneficial effect of low dose (81
mg or 325 mg) aspirin relative to higher doses (650 mg or
1300 mg).11 Thus, in this setting, aspirin therapy alone is
not sufficient to prevent platelet-mediated events. A recent
study from this center,12 which measured platelet reactivity
in patients before carotid surgery, found that those patients
with the highest numbers of embolic signals after surgery
(determined with transcranial Doppler scan) had platelets
that showed the greatest response to ADP before surgery.
This was despite all patients taking 150 mg aspirin per day,
and thromboembolic events did not correlate with the
patient response to aspirin. These data strongly suggest that
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there may be a role for specific ADP receptor antagonists in
carotid artery surgery, in addition to aspirin.
Studies in animals have indicated that aspirin enhances
the antithrombotic efficacy of theinopyridines,13-15 with
only limited hemostatic impairment.13-15 There is, how-
ever, little information on the effects of combining aspirin
and clopidogrel therapy on bleeding time (BT) plus platelet
function in humans. Most clinical experience with combi-
nation aspirin and ticlopidine or clopidogrel is in patients
undergoing percutaneous transluminal angioplasty and
stenting of coronary arteries.16-18 In this setting, patients
need small arterial puncture wounds to provide intraarterial
access, and reports have indicated that the incidence rate of
bleeding in patients with combined aspirin and ticlopidine
or clopidogrel therapy was less than that with conventional
anticoagulant regimes (generally heparin and warfarin).
However, in considering the use of ADP receptor antago-
nists in combination with aspirin in open vascular surgery, a
balance must be sought between prevention of thrombo-
embolic events and achievement of adequate hemostasis.
To address this issue, we conducted a study in healthy male
subjects for the evaluation of the effects of aspirin alone or
in combination with clopidogrel bisulfate on BT, platelet
aggregation, and activation.
METHOD
Study design. Seven healthy, nonsmoking male sub-
jects were studied, with ages ranging from 24 to 36 years
(median, 30 years) and an average weight of 79.4 kg (range,
74 to 85 kg). Before the study, each volunteer underwent a
full blood count and standard clotting screen to exclude
underlying hematologic disorders. Subjects were also ques-
tioned concerning aspirin intolerance and to confirm that no
cyclooxygenase inhibitor had been taken in the month before
the study. The study was approved by the Ethics Committee
of the Leicestershire University Hospitals’ Trust.
Blood samples were collected at four timepoints for mea-
surement of platelet activity. Baseline blood samples were
collected on day 0 at 9 AM. The subjects then were given 150
mg aspirin (The Wallis Laboratory Ltd, Luton, England), and
a second set of blood samples was taken 4 hours later. At 24
and 48 hours, the subjects received 75 mg of oral clopidogrel
(Plavix; Bristol-Myers Squibb, Middlesex, United Kingdom)
together with 150 mg aspirin per day. The third blood sample
was collected on day 3 at 9 AM. The subjects then were given
300 mg of clopidogrel, and a final set of blood samples was
collected 5 hours later. The doses of clopidogrel were chosen
to give suboptimal and maximal ADP receptor inhibition. The
300 mg dose of clopidogrel induces a similar level of platelet
inhibition to that seen in patients with 75 mg once a day on a
long-term basis.
Blood was collected from the antecubital fossa with a
standardized phlebotomy technique with minimal stasis,
designed to minimize platelet activation.19 Subjects were
rested for 20 minutes before blood was collected via a
21-gauge butterfly needle into vacutainer tubes (Becton
Dickinson, Oxford, United Kingdom). The first 3 mL of
blood were taken into ethylenediamine tetraacetic acid (4.5
mg) and used to obtain a full blood count (ACT Diff
Analyser, Coulter Electronics Ltd, Luton, United King-
dom). Subsequent samples were taken into trisodium ci-
trate (3.8% weight/volume) and processed for platelet
aggregometry and flow cytometry.
Bleeding time measurement. BT measurements were
performed on each of the four occasions in the contralateral
arm immediately after the collection of blood samples times
described previously. Measurements were performed by a
single individual (P.B.) with extensive experience with this
technique. All tests were performed on the volar surface of
the forearm with a sphygmomanometer inflated to 40 mm
Hg. Standardized incisions (5 mm long, 1 mm deep) were
made parallel to the axis of the forearm with a dual blade
spring-loaded device (Simplate IIR, Organon Teknika,
Cambridge, UK). Excess blood was removed from the cut
at 30-second intervals with blotting paper and with care to
avoid contact with the wound. The BT was measured as the
time of the incision to the time bleeding stopped. If bleed-
ing exceeded 30 minutes (a time period agreed on by the
Ethical Committee), compression was applied to the
wound until bleeding stopped and the BT was recorded as
30 minutes.
Platelet aggregometry. Platelet rich plasma was pre-
pared from citrated blood with centrifugation for 20 min-
utes at 160g. Platelet aggregation in response to 4  10–6
mol/L ADP (Sigma, Poole, UK), 6 10–6 mol/L throm-
bin receptor agonist peptide (TRAP) and SFLLRN peptide
were synthesized in house by University of Leicester Pro-
tein & Nucleic Acid Laboratory, and 1.0  103 g/L
collagen (Horm collagen, Nycomed, Cambridge, UK) was
monitored with a PAP-4 aggregometer (Bio/Data Corpo-
ration, Alpha Laboratories Ltd, Hants, United Kingdom)
as previously described.20 Aggregation was recorded as the
percentage of maximal aggregation, compared with light
transmission through autologous platelet poor plasma.
Whole blood flow cytometric analysis. Whole blood
flow cytometry was performed as described previously.19,20
Samples were processed within 10 minutes of collection,
with addition of 5 L citrated blood with 50 L Hepes-
buffered saline solution containing appropriate fluorescein
isothiocyanate (FITC)–conjugated antibodies and agonists
and incubating for 20 minutes at room temperature (20° C
to 22° C). Levels of glycoprotein (GP) IIb/IIIa on un-
stimulated platelets (expressed as mean fluorescence) were
measured with a CD41/61 Mab, RFGP56, raised in house,
and purified and conjugated to FITC by Cymbus Biotech-
nology Ltd (Chandlersford, Hants, United Kingdom).
Platelet-bound fibrinogen was measured with a FITC-
conjugated rabbit antibody to human fibrinogen (Rfgn-
FITC; Dako Ltd, High Wycombe, United Kingdom), and
P-selectin expression was measured with a FITC-conju-
gated CD62P Mab, AK-6 (Serotec, Oxford, United King-
dom). Samples were analyzed without stimulation and in
response to ADP (10–7, 10–6, and 10–5 mol/L) and TRAP
(5  10–6 mol/L). At the end of the 20-minute incuba-
tion, the samples were diluted 100 times in formyl saline
solution (0.2% [volume/volume] formaldehyde in 0.9%
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[weight/volume] NaCl) and analyzed, within 2 hours, in a
Beckman Coulter MCL-XL flow cytometer (Beckman
Coulter Ltd, Milton Keynes, UK). Fibrinogen binding and
P-selectin expression are expressed as the percentage of
platelets found positive for binding of fluorescent antibody.
Negative controls for GPIIb/IIIa and P-selectin expression
were set at 2% with FITC-conjugated IgG Mab,
MOPC21C (Sigma). The negative control for fibrinogen
binding was an unstimulated sample incubated with
Rfgn-FITC in the presence of 6 mol/L ethylenediamine
tetraacetic acid.
Statistical analysis. All data were analysed as the
mean the standard deviation and presented graphically as
the mean the standard error of the mean. Comparison of
the different treatment groups was with analysis of variance,
and 95% confidence intervals (CIs) are stated. Comparison
of the variability of platelet fibrinogen binding in the high
and low ADP responder groups (Fig 1) was by two-way
analysis of variance, with the assumption of unequal vari-
ance. A P value of .05 or less was considered as statistically
significant.
RESULTS
Effect on bleeding time of aspirin alone or aspirin
combined with clopidogrel. A standard hematologic
screen in the seven subjects showed no underlying abnor-
malities. The baseline BT was 5.1  1.9 minutes (mean 
standard deviation), and all subjects had BTs within the
healthy laboratory range of 4 to 10 minutes (Fig 2). Inges-
tion of 150 mg aspirin increased BT in six of the seven
subjects, resulting in a nonsignificant increase in the BT to
7.6 3.4 minutes (P .05; 95% CI, –7.4 to 12.2). After 2
days of treatment with 75 mg clopidogrel and 150 mg
aspirin per day, there was a significant 3.4-fold increase in
BT relative to baseline to 17.5 8.6 minutes (P	 .01; 95%
CI, 2.9 to 22.6). The BT was increased above the healthy
range in six of the seven subjects. When the clopidogrel
dose was increased to 300 mg, there was a significant
five-fold increase in BT relative to baseline to 24.9  8.5
minutes (P	 .001; 95% CI, 10.0 to 29.6). After 300 mg of
clopidogrel, there was a 47% increase in the BT relative to
low dose clopidogrel (P  .05; 95% CI, –2.8 to 16.9). All
subjects who received aspirin plus 2 days of 75 mg clopi-
dogrel achieved hemostasis within the 30-minute time limit
set for the BT, but with high-dose clopidogrel, three of the
seven subjects needed compression at 30 minutes to stop
bleeding from the forearm incision and two of these three
had oozing from the BT wound within the subsequent 4
hours. It is likely that if the bleeding had been allowed to
continue for an increased period of time, then there would
have been a significant difference between the 75 mg and
300 mg of clopidogrel bisulfate in terms of BT.
Ex vivo platelet aggregation. ADP-induced platelet
aggregation was significantly reduced from a baseline level
of 71.5%  26.2% to 47.9%  21.0% after aspirin (Fig 2).
This was further reduced to 34.7%  21.1% aggregation
after 2 days of aspirin with 75 mg clopidogrel. Clopidogrel
at 300 mg with aspirin gave a further reduction in ADP-
induced platelet aggregation to 24.9%  27.4%. These
reductions in aggregatory response were all significantly
different from the baseline values and significantly different
from each other (P 	 .05 for all).
Collagen-induced aggregation showed a similar signif-
icant trend to that seen with ADP (Fig 2), dropping from
85.9%  6.4% to 48.8%  10.5% with aspirin to 31.5% 
10.7% with aspirin plus low dose clopidogrel and to 16.6%
 26.7% with aspirin and high dose clopidogrel bisulfate
(P 	 .01 for all). Aggregation in response to TRAP was
significantly reduced with aspirin alone (P 	 .05), but
addition of either 2 75 mg or 300 mg clopidogrel did not
produce a further significant reduction in TRAP-induced
platelet aggregation (Fig 2).
Whole blood flow cytometric analysis. The effects of
the antiplatelet drugs on the platelet response to agonist
stimulation, measured with flow cytometry, were similar to
the results seen with aggregometry (Fig 3). Fibrinogen
binding in response to ADP was reduced by 21% after
aspirin ingestion from 63.5%  24.4% to 50.3%  18.9%
(P	 .05). Addition of 2 75 mg clopidogrel bisulfate and
300 mg clopidogrel gave further decreases in ADP-induced
fibrinogen binding to 40.8  29.1 (36% reduction from
baseline) and 24.1  19.1 (62% reduction from baseline),
respectively. These reductions were both statistically signifi-
cantly different from baseline (P 	 .05). However, although
high dose clopidogrel gave a more than 40% reduction in
ADP-induced fibrinogen binding to platelets when compared
with low dose clopidogrel, this did not differ statistically,
reflecting the high degree of intersubject variability in the
response to the drug.
Aspirin produced a small (9%) but nonsignificant re-
duction in TRAP-induced fibrinogen binding. Addition of
2  75 mg clopidogrel gave a larger (48%; P  .05)
decrease over and above that seen with aspirin alone, but
increasing the dose of clopidogrel to 300 mg did not cause
any further decrease in TRAP-induced fibrinogen binding.
Fig 1. Template bleeding time measurements in healthy subjects
(n  7) given aspirin (150 mg), aspirin (150 mg/day) and clopi-
dogrel (75 mg/day; AspC75) for 2 days, and aspirin (150 mg)
and clopidogrel (300 mg; AspC300). Results are expressed as
mean  standard error of mean.
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P-selectin expression in response to ADP and TRAP
was not significantly reduced with any of the treatments
(data not shown). Neither aspirin alone nor aspirin in
combination with either dose of clopidogrel significantly
affected the levels of bound fibrinogen or P selectin on
unstimulated platelets, which were less than 3% in all cases,
and expression of GPIIb/IIIa remained unchanged (P .3
for all; data not shown).
Intersubject variability in response to clopidogrel
bisulfate. There was considerable variability between indi-
viduals in response to ADP at baseline and subsequent
response to low dose of clopidogrel. This is illustrated with
the subject platelet fibrinogen binding in response to ADP
(Fig 4). Subjects were divided into those who, at baseline,
had higher than average levels of bound fibrinogen in
response to ADP (n 3) and those with lower than average
responses (n  4). With aspirin alone, both low ADP and
high ADP responders showed a similar significant reduc-
tion in platelet fibrinogen binding at all levels of ADP used
(Fig 4). The response to 2  75 mg clopidogrel was,
however, different between the two groups. Low baseline
ADP responders showed a significant fall (45% from base-
Fig 2. Effects of aspirin alone or in combination with low dose (2  75 mg; C75) or high dose (300 mg; C300)
clopidogrel on platelet aggregation in response to adenosine diphosphate (ADP ; 106 mol/L), collagen (1.0 103
g/mL), and thrombin receptor agonist peptide (TRAP ; 6  10–6 mol/L). Results are expressed as mean  standard
error of mean.
Fig 3. Effects of aspirin alone or in combination with low dose (2  75 mg; C75) or high dose (300 mg; C300)
clopidogrel on platelet activation markers in response to adenosine diphosphate (ADP ; 10–6 mol/L) and thrombin
receptor agonist peptide (TRAP; 6 10–6 mol/L), measured with whole blood flow cytometry. Results are expressed
as mean  standard error of mean.
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Payne et al 1207
line) in ADP-mediated platelet activation with the lower
dose of clopidogrel and no subsequent fall in ADP response
when the clopidogrel dose was increased to 300 mg. In
contrast, the high ADP responders showed relatively little
reduction in response to ADP with low dose clopidogrel
(17.5% fall from baseline) but a large drop in ADP response
(75.7% from baseline) after the higher clopidogrel dose.
Despite these relative differences in the response to the
lower dose of clopidogrel, the level of fibrinogen binding in
response to ADP with the 300 mg dose of clopidogrel was
similar in all subjects. There were similar findings with the
aggregatory response to ADP (data not shown).
DISCUSSION
Although standard doses of aspirin can reduce the
incidence rate of thromboembolic events, the effect is only
partial2 and does not inhibit the effect of physiologic ago-
nists, such as ADP, directly. Long-term prophylactic treat-
ment with the ADP receptor antagonists ticlopidine hydro-
chloride or clopidogrel bisulfate5-7 has shown a small but
significant benefit over aspirin alone, with no increase in
bleeding. In the more acute setting of intracoronary inter-
vention, a combination of aspirin and theinopyridine re-
duced thrombotic events without an increased incidence of
bleeding, either after surgery or systemically, compared
with conventional antithrombotic regimes.16-18 This begs
the question of whether combined therapy with these drugs
would be beneficial in other vascular interventions, includ-
ing open arterial surgery.
Therapeutically active doses of both ticlopidine and
clopidogrel have been shown to prolong the BT in hu-
mans,21,22 but there have been relatively few studies of the
combined effects of clopidogrel with aspirin on bleeding
risk in humans.23 The combination of aspirin and ticlopi-
dine or clopidogrel has been shown to have additive effects
on ex vivo platelet function and in animal models of acute
and subacute thrombosis with only a modest increase in
BT.12-15 There has been only one reported study of com-
bination antiplatelet therapy in open surgery, with no sys-
tematic assessment of bleeding.24
The doses of clopidogrel used in this study were chosen
to represent a submaximal (2 days at 75 mg per day) and
maximum (300 mg for 5 hours) level of platelet inhibi-
tion.25,26 Prolongation of the BT was seen with low-dose
clopidogrel and aspirin in all but one subject, and pro-
longed bleeding was seen in all subjects after high dose
clopidogrel with aspirin. This was reflected in concomitant
reductions in platelet aggregation and fibrinogen binding
in response to ADP and collagen. The reduction in platelet
function with high dose clopidogrel, measured with flow
cytometry, was not statistically different from low dose
clopidogrel. This was because subjects with a low baseline
response to ADP achieved maximal antiplatelet effect with
the low dose of clopidogrel. Increasing the dose to 300 mg
had little or no effect on ex vivo platelet function in these
individuals, whereas the BT increased significantly.
Variability in response to clopidogrel has been previ-
ously ascribed to differences in drug metabolism or body
weight between individuals, although this was not born out
by the CAPRIE study.5 The subjects in this study showed
relatively little variation in body weight (74 to 85 kg), and
there was no correlation between this variation and re-
Fig 4. Adenosine diphosphate (ADP)–induced platelet fibrinogen binding, measured with whole blood flow cytom-
etry. Measurements were made at baseline (continuous line), after aspirin therapy alone (dotted line), or with aspirin
therapy in combination with low dose (2 75 mg; dashed line) or high dose (300 mg; dashed/dotted line) clopidogrel
bisulfate. Subjects are divided into those with lower than average response to ADP (low ADP responders ; n  3) and
those with higher than average response to ADP (high ADP responders ; n  4). Data are shown as mean  standard
error of mean.
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sponse to clopidogrel. It would appear from this study that
variability in response to clopidogrel is more closely linked
to the ADP responsiveness of the subject platelets; those
subjects with a high level of response to ADP needed a
higher dose of clopidogrel to achieve maximum inhibition
of ADP response.
There was no direct correlation between BT before or
after treatment and the individual platelet response to agonists
or to clopidogrel. This reflects the acknowledged variability
and imprecision of standard BT measurements.27 Although
BT measurement also shows a relatively poor correlation with
surgical bleeding,28 it is a measure of the overall platelet
hemostatic function and can be used to show the hemorrhagic
effect of antiplatelet drugs. Newer laboratory-based methods,
such as the PFA-100 analyzer,29 may give a more relevant
measure of the individual patient bleeding risk, but such a
correlation has yet to be established.
TRAP-induced platelet aggregation and activation
were reduced with the low dose of clopidogrel and aspirin,
but increasing the dose of clopidogrel to 300 mg gave no
further reduction in the thrombin response. Thus, platelet
response to thrombin can be maintained, allowing a degree of
hemostasis in the face of selective inhibition of thrombox-
ane and ADP-mediated platelet activation, confirming ear-
lier studies in a baboon model.15
Taken together, these data suggest that combining
clopidogrel with aspirin for major cardiovascular or general
surgical procedures may carry a significantly increased risk
of bleeding. The recent CURE study has shown a signifi-
cant benefit for the simultaneous administration of both
drugs in the prevention of acute coronary syndromes.30 It
seems likely that patients undergoing chronic dual therapy
will increasingly need consideration of vascular surgical
intervention, and the significant potential for increased
bleeding should be carefully considered.
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